This web site is part of the Business Intelligence Division of Informa PLC
Western Oncolytics Ltd.
Drug Names(s): WO12, WO 12
Description: WO-12 is a novel oncolytic vaccinia virus. As an in vivo vaccine, it has the potential to be delivered directly to the tumor (intratumoral) or intravenously. More specifically, it is a virus engineered to replicate primarily in cancer cells while delivering several therapeutic genes that modulate the immune system to enhance efficacy against a range of cancers.
Pfizer and Western Oncolytics
In July 2016, Pfizer and Western Oncolytics entered into a development collaboration, license and option agreement to advance Western Oncolytics novel oncolytic vaccinia virus, WO-12. Under the terms of the agreement, Pfizer and Western Oncolytics will collaborate on preclinical and clinical development of WO-12 through Phase I trials. Following completion of Phase I trials, Pfizer has an exclusive option to acquire WO-12. Financial terms of the agreement were not disclosed.
Partners: Pfizer Inc.
Pink Sheet Weekly Trademark Review Jan. 17, 2017
Pink Sheet Recent FDA OTC Drug Recalls
Additional information available to subscribers only: